Blueprint Medicines CorpNASDAQ:BPMC
- LAST PRICE89.3900
- TODAY'S CHANGE (%)-6.2600 (-6.5447%)
- Bid / Lots89.2900/ 6
- Ask / Lots89.6000/ 6
- Open / Previous Close96.3400 / 95.6500
- Day Range
- 52 Week Range
- Volume548,217
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BPMC |
|---|---|---|
| 09:32 ET | 17348 | 95.905 |
| 09:33 ET | 600 | 95.16 |
| 09:35 ET | 3198 | 94.55 |
| 09:37 ET | 1500 | 94.945 |
| 09:39 ET | 2101 | 94.425 |
| 09:42 ET | 300 | 94.52 |
| 09:44 ET | 845 | 94.55 |
| 09:46 ET | 2500 | 94.45 |
| 09:48 ET | 3330 | 94.71 |
| 09:50 ET | 7835 | 94.5 |
| 09:51 ET | 200 | 94.5 |
| 09:53 ET | 6941 | 94.38 |
| 09:55 ET | 400 | 94.37 |
| 09:57 ET | 743 | 94.25 |
| 10:00 ET | 3210 | 94.25 |
| 10:02 ET | 2210 | 94.285 |
| 10:04 ET | 2121 | 94.22 |
| 10:06 ET | 2100 | 94 |
| 10:08 ET | 1822 | 94.01 |
| 10:09 ET | 28011 | 94.13 |
| 10:11 ET | 1800 | 94.31 |
| 10:13 ET | 11514 | 93.935 |
| 10:15 ET | 10602 | 93.84 |
| 10:18 ET | 2500 | 93.85 |
| 10:20 ET | 3360 | 93.675 |
| 10:22 ET | 10887 | 92.92 |
| 10:24 ET | 3358 | 93.03 |
| 10:26 ET | 1400 | 93.33 |
| 10:27 ET | 68302 | 92.87 |
| 10:29 ET | 13000 | 92.48 |
| 10:31 ET | 700 | 92.05 |
| 10:33 ET | 1548 | 91.96 |
| 10:36 ET | 1286 | 92.155 |
| 10:38 ET | 5517 | 92.5 |
| 10:40 ET | 6900 | 92.56 |
| 10:42 ET | 800 | 92.535 |
| 10:44 ET | 5700 | 92.33 |
| 10:45 ET | 6574 | 91.73 |
| 10:47 ET | 5985 | 91.815 |
| 10:49 ET | 1823 | 91.69 |
| 10:51 ET | 1902 | 91.67 |
| 10:54 ET | 993 | 91.515 |
| 10:56 ET | 5100 | 91.305 |
| 10:58 ET | 810 | 91.05 |
| 11:00 ET | 673 | 91.38 |
| 11:02 ET | 800 | 90.935 |
| 11:03 ET | 499 | 91 |
| 11:05 ET | 6932 | 90.65 |
| 11:07 ET | 1100 | 90.85 |
| 11:09 ET | 4113 | 90.575 |
| 11:12 ET | 1397 | 90.31 |
| 11:14 ET | 300 | 90.25 |
| 11:16 ET | 2077 | 90.69 |
| 11:18 ET | 200 | 90.78 |
| 11:20 ET | 454 | 90.835 |
| 11:21 ET | 1600 | 91.235 |
| 11:23 ET | 1741 | 91.26 |
| 11:25 ET | 200 | 91.3 |
| 11:27 ET | 700 | 91.05 |
| 11:30 ET | 6893 | 91.06 |
| 11:32 ET | 1900 | 90.995 |
| 11:34 ET | 100 | 91.11 |
| 11:36 ET | 400 | 90.86 |
| 11:38 ET | 500 | 90.92 |
| 11:39 ET | 400 | 90.9 |
| 11:41 ET | 100 | 90.86 |
| 11:43 ET | 24986 | 90.9025 |
| 11:45 ET | 607 | 91.146 |
| 11:48 ET | 300 | 91.075 |
| 11:50 ET | 500 | 91.065 |
| 11:52 ET | 400 | 90.9 |
| 11:54 ET | 1284 | 91.1 |
| 11:56 ET | 900 | 91.24 |
| 11:57 ET | 300 | 91.14 |
| 11:59 ET | 3244 | 90.82 |
| 12:01 ET | 200 | 90.86 |
| 12:03 ET | 1165 | 90.83 |
| 12:06 ET | 300 | 90.79 |
| 12:08 ET | 600 | 90.86 |
| 12:10 ET | 500 | 90.905 |
| 12:12 ET | 1500 | 90.98 |
| 12:14 ET | 600 | 90.96 |
| 12:15 ET | 1600 | 91.19 |
| 12:17 ET | 1600 | 91.5 |
| 12:19 ET | 700 | 91.5 |
| 12:21 ET | 880 | 91.475 |
| 12:24 ET | 500 | 91.4 |
| 12:26 ET | 100 | 91.43 |
| 12:28 ET | 600 | 91.425 |
| 12:30 ET | 300 | 91.19 |
| 12:32 ET | 1400 | 91.14 |
| 12:33 ET | 200 | 90.97 |
| 12:35 ET | 1300 | 91.03 |
| 12:37 ET | 3900 | 90.74 |
| 12:39 ET | 400 | 90.615 |
| 12:42 ET | 603 | 90.62 |
| 12:44 ET | 700 | 90.4337 |
| 12:46 ET | 842 | 90.48 |
| 12:48 ET | 2000 | 90.59 |
| 12:50 ET | 1992 | 90.67 |
| 12:51 ET | 500 | 90.53 |
| 12:53 ET | 600 | 90.565 |
| 12:55 ET | 300 | 90.51 |
| 12:57 ET | 848 | 90.42 |
| 01:00 ET | 800 | 90.47 |
| 01:02 ET | 2200 | 90.51 |
| 01:04 ET | 2200 | 90.53 |
| 01:06 ET | 100 | 90.43 |
| 01:08 ET | 800 | 90.53 |
| 01:09 ET | 2729 | 90.375 |
| 01:11 ET | 2988 | 90.23 |
| 01:13 ET | 1673 | 90.21 |
| 01:15 ET | 3818 | 90.24 |
| 01:18 ET | 3687 | 90.3 |
| 01:20 ET | 1000 | 90.355 |
| 01:22 ET | 5873 | 90.33 |
| 01:24 ET | 1370 | 90.24 |
| 01:26 ET | 700 | 90.145 |
| 01:27 ET | 891 | 90.25 |
| 01:29 ET | 1304 | 90.45 |
| 01:31 ET | 1400 | 90.12 |
| 01:33 ET | 500 | 90.2 |
| 01:36 ET | 300 | 90.12 |
| 01:38 ET | 1100 | 90.25 |
| 01:40 ET | 4464 | 90 |
| 01:42 ET | 4400 | 90 |
| 01:44 ET | 601 | 89.85 |
| 01:45 ET | 691 | 89.71 |
| 01:47 ET | 2579 | 89.97 |
| 01:49 ET | 500 | 89.76 |
| 01:51 ET | 16726 | 89.725 |
| 01:54 ET | 1800 | 89.42 |
| 01:56 ET | 7300 | 89.23 |
| 01:58 ET | 469 | 89.15 |
| 02:00 ET | 1400 | 89.185 |
| 02:02 ET | 500 | 89.16 |
| 02:03 ET | 1600 | 89.325 |
| 02:05 ET | 400 | 89.39 |
Today
Yesterday
DJ Blueprint Medicines Initiated at Overweight by JP Morgan, from 7:48AM ET on Thursday Nov 14, 2024 by Dow Jones
7:48AM ET on Thursday Nov 14, 2024 by Dow Jones
Oct 31, 2024
DJ Blueprint Medicines Is Maintained at Overweight by Wells Fargo, from 3:56PM ET on Thursday Oct 31, 2024 by Dow Jones
3:56PM ET on Thursday Oct 31, 2024 by Dow JonesDJ Blueprint Medicines Price Target Maintained With a $135.00/Share by HC Wainwright & Co., from 8:23AM ET on Thursday Oct 31, 2024 by Dow Jones
8:23AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Blueprint Medicines Corp | 6.1B | -42.4x | --- |
ADMA Biologics Inc | 4.8B | 69.2x | --- |
TG Therapeutics Inc | 4.8B | -274.1x | --- |
Legend Biotech Corp | 7.4B | -25.0x | --- |
Axsome Therapeutics Inc | 4.7B | -14.3x | --- |
Viking Therapeutics Inc | 6.0B | -53.4x | --- |
Company Information
Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.
Contact Information
- Headquarters
- 45 Sidney StreetCAMBRIDGE, MA, United States 02139
- Phone
- 617-374-7580
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Jeffrey Albers
- President, Chief Executive Officer, Director
- Kathryn Haviland
- Chief Financial Officer
- Michael Landsittel
- President - Research and Development
- Fouad Namouni
- Chief Operating Officer
- Christina Rossi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.1B |
|---|---|
Revenue (TTM) | $434.4M |
Shares Outstanding | 63.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.58 |
EPS | $-2.11 |
Book Value | $2.14 |
P/E Ratio | -42.4x |
Price/Sales (TTM) | 14.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -23.54% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
